Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04380701
Recruitment Status : Recruiting
First Posted : May 8, 2020
Last Update Posted : April 22, 2021
Sponsor:
Information provided by (Responsible Party):
BioNTech SE

Tracking Information
First Submitted Date  ICMJE May 6, 2020
First Posted Date  ICMJE May 8, 2020
Last Update Posted Date April 22, 2021
Actual Study Start Date  ICMJE April 23, 2020
Estimated Primary Completion Date April 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 1, 2021)
  • Solicited local reactions at the injection site (pain, tenderness, erythema/redness, induration/swelling) recorded up to 7 days after each immunization. [ Time Frame: up to 7 days following each dose administration ]
  • Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7 days after each immunization. [ Time Frame: up to 7 days following each dose administration ]
  • The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE): [ Time Frame: 21 days following dose administration ]
    For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B): occurring up to 21 days after the prime immunization.
  • The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE): [ Time Frame: 28 days following dose administration ]
    For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B): occurring up to 28 days after the boost immunization. For BNT162c2 (SD): The proportion of subjects with at least 1 unsolicited TEAE occurring up to 28 days after the immunization.
Original Primary Outcome Measures  ICMJE
 (submitted: May 7, 2020)
  • Solicited local reactions at the injection site (pain, tenderness, erythema/redness, induration/swelling) recorded up to 7±1 days after each immunization. [ Time Frame: up to 7 days following each dose administration ]
  • Solicited systemic reactions (nausea, vomiting, diarrhea, headache, fatigue, myalgia, arthralgia, chills, loss of appetite, malaise, and fever) recorded up to 7±1 days after each immunization. [ Time Frame: up to 7 days following each dose administration ]
  • The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE): [ Time Frame: 21 days following dose administration ]
    For BNT162a1, BNT162b1, BNT162b2 (P/B): occurring up to 21±2 days after the prime immunization.
  • The proportion of subjects with at least 1 unsolicited treatment emergent adverse event (TEAE): [ Time Frame: 28 days following dose administration ]
    For BNT162a1, BNT162b1, BNT162b2 (P/B): occurring up to 28±4 days after the boost immunization. For BNT162c2 (SD): The proportion of subjects with at least 1 unsolicited TEAE occurring up to 28±4 days after the immunization.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 20, 2021)
  • For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B): [ Time Frame: up to 162 days following dose administration ]
    Functional antibody responses (titers) as compared to baseline at 7 and 21 days after primary immunization and at 7, 14, 21, 28, 63, and 162 days after the boost immunization.
  • For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B): [ Time Frame: up to 162 days following dose administration ]
    Fold increase in functional antibody titers as compared to baseline at 7 and 21 days after primary immunization and at 7, 14, 21, 28, 63, and 162 days after the boost immunization.
  • For BNT162a1, BNT162b1, BNT162b2, and BNT162c2 (P/B): [ Time Frame: up to 162 days following dose administration ]
    Number of subjects with seroconversion defined as a minimum of 4-fold increase of functional antibody titers as compared to baseline at 7 and 21 days after primary immunization and at 7, 14, 21, 28, 63, and 162 days after the boost immunization.
  • For BNT162c2 (SD): [ Time Frame: up to 183 days following dose administration ]
    Functional antibody responses (titers) as compared to baseline at 7, 21, 28, 42, 84, and 183 days after the primary immunization.
  • For BNT162c2 (SD): [ Time Frame: up to 183 days following dose administration ]
    Fold increase in functional antibody titers as compared to baseline at 7, 21, 28, 42, 84, and 183 days after the primary immunization.
  • For BNT162c2 (SD): [ Time Frame: up to 183 days following dose administration ]
    Number of subjects with seroconversion defined as a minimum of 4-fold increase of functional antibody titers as compared to baseline at 7, 21, 28, 42, 84, and 183 days after the primary immunization.
  • For BNT162b2 (P/B): [ Time Frame: up to 162 days following dose administration ]
    Functional antibody responses (titers) as compared to baseline at 7, 14, and 21 days after the primary immunization and at 7, 28, and 162 days after the boost immunization.
  • For BNT162b2 (P/B): [ Time Frame: up to 162 days following dose administration ]
    Fold increase in functional antibody titers as compared to baseline at 7, 14, and 21 days after primary immunization and at 7, 28, and 162 days after the boost immunization.
  • For BNT162b2 (P/B): [ Time Frame: up to 162 days following dose administration ]
    Number of subjects with seroconversion defined as a minimum of 4-fold increase of functional antibody titers as compared to baseline at 7, 14, and 21 days after primary immunization and at 7, 28, and 162 days after the boost immunization.
Original Secondary Outcome Measures  ICMJE
 (submitted: May 7, 2020)
  • For BNT162a1, BNT162b1, BNT162b2 (P/B): [ Time Frame: up to 162 days following dose administration ]
    Functional antibody responses at 7±1 days and 21±2 days after primary immunization and at 21±2 days, 63±5 days, and 162±7 days after the boost immunization.
  • For BNT162a1, BNT162b1, BNT162b2 (P/B): [ Time Frame: up to 162 days following dose administration ]
    Fold increase in functional antibody titers 7±1 days and 21±2 days after primary immunization and at 21±2 days, 63±5 days, and 162±7 days after the boost immunization.
  • For BNT162a1, BNT162b1, BNT162b2 (P/B): [ Time Frame: up to 162 days following dose administration ]
    Number of subjects with seroconversion defined as a minimum of 4-fold increase of functional antibody titers as compared to baseline at 7±1 days and 21±2 days after primary immunization and at 21±2 days, 63±5 days, and 162±7 days after the boost immunization.
  • For BNT162c2 (SD): [ Time Frame: up to 183 days following dose administration ]
    Functional antibody responses at 7±1 days, 21±2 days, 42±3 days, 84±5 days, and 183±7 days after the primary immunization.
  • For BNT162c2 (SD): [ Time Frame: up to 183 days following dose administration ]
    Fold increase in functional antibody titers at 7±1 days, 21±2 days, 42±3 days, 84±5 days, and 183±7 days after the primary immunization.
  • For BNT162c2 (SD): [ Time Frame: up to 183 days following dose administration ]
    Number of subjects with seroconversion defined as a minimum of 4-fold increase of functional antibody titers as compared to baseline at 7±1 days, 21±2 days, 42±3 days, 84±5 days, and 183±7 days after the primary immunization.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults
Official Title  ICMJE A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy and Immunocompromised Adults
Brief Summary

This trial has two parts. Part A and Part B. Due to changes in the overall clinical development plan, Part B will no longer be conducted. The objectives originally described for Part B have been implemented in the ongoing development via a pivotal Phase I/II/III trial BNT162-02/C4591001 (ClinicalTrials.gov NCT: 04368728).

Part A is for dose ranging of four different vaccines (BNT162a1, BNT162b1, BNT162b2, and BNT162c2) which will be undertaken with dose escalation and de-escalation plus the evaluation of interim dose levels. It also includes dose ranging in older participants.

The vaccines BNT162a1, BNT162b1, BNT162b2, and BNT162c2 will be administered using a Prime/Boost (P/B) regimen. The vaccine BNT162c2 will also be administered using a Single dose (SD) regimen. Three additional cohorts aged from 18 to 85 years receiving BNT162b2 only.

BNT162b2 has entered a Phase II/III evaluation of efficacy, with the intent to support an application for marketing authorization. The dosing regimen under investigation is two BNT162b2 doses given ~21 d apart.

Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Infections, Respiratory
  • Virus Diseases
  • Infection Viral
  • Vaccine Adverse Reaction
  • RNA Virus Infections
  • Protection Against COVID-19 and Infections With SARS CoV 2
Intervention  ICMJE
  • Biological: BNT162a1
    Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
  • Biological: BNT162b1
    Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
  • Biological: BNT162b2
    Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
  • Biological: BNT162c2
    Anti-viral RNA vaccine for active immunization against COVID-19 administered as intramuscular injection.
Study Arms  ICMJE
  • Experimental: BNT162a1 (P/B) - Part A 18-55 years of age
    Escalating dose levels
    Intervention: Biological: BNT162a1
  • Experimental: BNT162b1 (P/B) - Part A 18-55 years of age
    Escalating dose levels
    Intervention: Biological: BNT162b1
  • Experimental: BNT162b2 (P/B) - Part A 18-55 years of age
    Escalating dose levels
    Intervention: Biological: BNT162b2
  • Experimental: BNT162c2 (P/B) - Part A 18-55 years of age
    Escalating dose levels
    Intervention: Biological: BNT162c2
  • Experimental: BNT162c2 (prime only) - Part A 18-55 years of age
    Single dose
    Intervention: Biological: BNT162c2
  • Experimental: BNT162b1 (P/B) - Part A 56-85 years of age
    Escalating dose levels
    Intervention: Biological: BNT162b1
  • Experimental: BNT162b2 (P/B) - Part A 56-85 years of age
    Escalating dose levels
    Intervention: Biological: BNT162b2
  • Experimental: BNT162b2 (P/B) - Part A 18-85 years of age (Expansion cohorts 11 to 13)
    Escalating dose levels
    Intervention: Biological: BNT162b2
  • Experimental: BNT162b2 (P/B) - Part A 18-85 years of age (Expansion cohort 14)
    Biomarker (B cell and plasma cell immunity)
    Intervention: Biological: BNT162b2
Publications * Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC, Hein S, Güler A, Loschko J, Maddur MS, Ota-Setlik A, Tompkins K, Cole J, Lui BG, Ziegenhals T, Plaschke A, Eisel D, Dany SC, Fesser S, Erbar S, Bates F, Schneider D, Jesionek B, Sänger B, Wallisch AK, Feuchter Y, Junginger H, Krumm SA, Heinen AP, Adams-Quack P, Schlereth J, Schille S, Kröner C, de la Caridad Güimil Garcia R, Hiller T, Fischer L, Sellers RS, Choudhary S, Gonzalez O, Vascotto F, Gutman MR, Fontenot JA, Hall-Ursone S, Brasky K, Griffor MC, Han S, Su AAH, Lees JA, Nedoma NL, Mashalidis EH, Sahasrabudhe PV, Tan CY, Pavliakova D, Singh G, Fontes-Garfias C, Pride M, Scully IL, Ciolino T, Obregon J, Gazi M, Carrion R Jr, Alfson KJ, Kalina WV, Kaushal D, Shi PY, Klamp T, Rosenbaum C, Kuhn AN, Türeci Ö, Dormitzer PR, Jansen KU, Sahin U. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021 Apr;592(7853):283-289. doi: 10.1038/s41586-021-03275-y. Epub 2021 Feb 1.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 20, 2021)
476
Original Estimated Enrollment  ICMJE
 (submitted: May 7, 2020)
200
Estimated Study Completion Date  ICMJE April 2023
Estimated Primary Completion Date April 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Have given informed consent by signing the informed consent form (ICF) before initiation of any trial-specific procedures.
  • They must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions (e.g., to practice social distancing and to follow good practices to reduce their chances of being infected or spreading COVID-19), and other requirements of the trial.
  • They must be able to understand and follow trial-related instructions.
  • For younger adult cohorts, volunteers must be aged 18 to 55 years, have a body mass index (BMI) over 19 kg/m^2 and under 30 kg/m^2, and weigh at least 50 kg at Visit 0. OR For older adult cohorts, volunteers must be aged 56 to 85 years, have a BMI over 19 kg/m^2 and under 30 kg/m^2, and weigh at least 50 kg at Visit 0. OR For the immunocompromised adult cohort (Cohort 13), volunteers must be aged 18 to 85 years, have a BMI over 19 kg/m^2 and under 30 kg/m^2, and weigh at least 50 kg at Visit 0.
  • They must be healthy, in the clinical judgment of the investigator, based on medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs (systolic/diastolic blood pressure, pulse rate, body temperature, respiratory rate), and clinical laboratory tests (blood chemistry, hematology, and urine chemistry) at Visit 0. Note: Healthy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included. OR For the immunocompromised cohort (Cohort 13); volunteers who have previously received solid organ transplant, or peripheral blood stem cell transplantation ≥6 months after transplantation, or individuals with human immunodeficiency virus (HIV) infection with a CD4+ T-cell count of ≥200 x 10^6 /L at Visit 0. Individuals with lower T-cell counts will be excluded from the trial on the basis that this represents a significant medical complication. In the clinical judgment of the investigator, volunteers must be immunocompromised but otherwise healthy. After consultation with the Medical Monitor, this may include individuals receiving immunosuppressant therapy due to another confounding disease at least 2 weeks prior to enrollment and/or at least 6 weeks following immunization with BNT162b2, and/or individuals with immunosuppressive treatment of an autoimmune disease if the disease is stable.
  • Women of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin urine test at Visit 0 and Visit 1. Women that are postmenopausal or permanently sterilized will be considered as not having reproductive potential.
  • WOCBP must agree to practice a highly effective form of contraception during the trial, starting after Visit 0 and continuously until 60 days after receiving the last immunization. WOCBP must agree to require their male partners to use condoms during sexual contact (unless male partners are sterilized or infertile).
  • WOCBP must confirm that they practice at least one highly effective form of contraception for the 14 days prior to Visit 0.
  • WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting after Visit 0 and continuously until 60 days after receiving the last immunization.
  • Men who are sexually active with a WOCBP and have not had a vasectomy must agree to practice a highly effective form of contraception with their female partner of childbearing potential during the trial, starting after Visit 0 and continuously until 60 days after receiving the last immunization.
  • Men must be willing to refrain from sperm donation, starting after Visit 0 and continuously until 60 days after receiving the last immunization.
  • They must have confirmation of their health insurance coverage prior to Visit 0.
  • They must agree to not be vaccinated during the trial, starting after Visit 0 and continuously until 28 days after receiving the last immunization.

Exclusion Criteria:

  • Have had any acute illness, as determined by the investigator, with or without fever, within 72 hours prior to the first immunization. An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the investigator, the residual symptoms will not compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
  • Are breastfeeding on the day of Visit 0 or who plan to breastfeed during the trial, starting after Visit 0 and continuously until at least 90 days after receiving the last immunization.
  • Have a known allergy, hypersensitivity, or intolerance to the planned investigational medicinal product (IMP) including any excipients of the IMP.
  • Had any medical condition or any major surgery (e.g., requiring general anesthesia) within the past 5 years which, in the opinion of the investigator, could compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
  • Have any surgery planned during the trial, starting after Visit 0 and continuously until at least 90 days after receiving the last immunization.
  • Had any chronic use (more than 21 continuous days) of any systemic medications, including immunosuppressant's or other immune-modifying drugs (except for Cohort 13), within the 6 months prior to Visit 0 unless in the opinion of the investigator, the medication would not prevent, limit, or confound the protocol-specified assessments or could compromise subject safety. Note: Healthy volunteers with pre-existing stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.
  • Had any vaccination within the 28 days prior to Visit 0.
  • Had administration of any immunoglobulins and/or any blood products within the 3 months prior to Visit 0.
  • Had administration of another investigational medicinal product including vaccines within 60 days or 5 half-lives (whichever is longer), prior to Visit 0.
  • Have a known history of active or ongoing hepatitis B or hepatitis C infection; or except for Cohort 13: HIV-1 or HIV-2 infection within the 30 days prior to Visit 0.
  • Have a positive polymerase chain reaction (PCR)-based test for SARS-CoV-2 within the 30 days prior to Visit 1.
  • Have a positive drugs of abuse (for amphetamines, benzodiazepines, barbiturates, cocaine, cannabinoids, opiates, methadone, methamphetamines, phencyclidine, and tricyclic antidepressants) result at Visit 0 or Visit 1.
  • Have a positive breath alcohol test at Visit 0 or Visit 1.
  • Previously participated in an investigational trial involving lipid nanoparticles.
  • Are subject to exclusion periods from other investigational trials or simultaneous participation in another clinical trial. When entering the follow-up phase, i.e., after completing the end of treatment (EoT) visit, subjects are allowed to participate in other clinical trials not investigating COVID-19 vaccines or treatments; subjects immunized with BNT162 vaccines in this clinical trial are allowed to participate in other clinical trials involving immunization with BNT162b2.
  • Have any affiliation with the trial site (e.g., are close relative of the investigator or dependent person, such as an employee or student of the trial site).
  • Have a history (within the past 5 years) of substance abuse or known medical, psychological, or social conditions which, in the opinion of the investigator, could compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.
  • Have a history of hypersensitivity or serious reactions to previous vaccinations.
  • Have a history of Guillain-Barré Syndrome within 6 weeks following a previous vaccination.
  • Have a history of narcolepsy.
  • Have history of alcohol abuse or drug addiction within 1 year before Visit 0.
  • (Except for Cohort 13) Have a history of or suspected immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination at Visit 0.
  • Have any abnormality or permanent body art (e.g., tattoo) that, in the opinion of the investigator, would obstruct the ability to observe local reactions at the injection site.
  • Have had any blood loss >450 mL, e.g., due to donation of blood or blood products or injury, within the 7 days prior to Visit 0 or plan to donate blood during the trial, starting after Visit 0 and continuously until at least 7 days after receiving the last immunization.
  • Have symptoms of COVID-19, e.g., respiratory symptoms, fever, cough, shortness of breath and breathing difficulties.
  • Have had contact with persons diagnosed with COVID-19 or who tested positive for SARS-CoV-2 by any diagnostic test within the 30 days prior to Visit 1.
  • Are soldiers, volunteers in detention, contract research organization (CRO) or sponsor staff or their family members.
  • Regular receipt of inhaled/nebulized corticosteroids (except for Cohort 13).
  • For older volunteers and for Cohort 13 only: Have a condition known to put them at high risk for severe COVID-19, including those with any of the following risk factors:
  • Uncontrolled hypertension.
  • Diabetes mellitus (HbA1c >8.5% ≥3 months, according to the medical history reported by the subject).
  • Chronic obstructive pulmonary disease.
  • Asthma.
  • Chronic liver disease.
  • Known Stage 3 or worse chronic kidney disease (glomerular filtration rate <60 mL/min/1.73 m^2); Except for post-renal transplant patients who should have (estimated) GFR ≥40 mL/min/1.73 m^2.
  • Serious heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies.
  • Sickle cell disease.
  • Cancer (except for Cohort 13).
  • Are immune compromised due to stem cell or organ-transplantation with significant medical complications such as acute or chronic graft rejection or graft versus host disease requiring intensive immunosuppressive treatment, transplant failure or infectious complications or other conditions that would be considered a contraindication for vaccination.
  • Are immune compromised due to HIV infection with a CD4+ count of < 200 x 10^6 /L at screening or significant medical complications such as opportunistic infections, malignant complications (e.g., lymphoma, Kaposi sarcoma), other organ manifestations consistent with advanced AIDS or other conditions that would be considered a contraindication for vaccination.
  • Resident in a long term facility.
  • Current vaping or smoking (occasional smoking is acceptable).
  • History of chronic smoking within the prior year.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: BioNTech clinical trials patient information +49 6131 9084 ext 1919 patients@biontech.de
Contact: BioNTech clinical trial information desk +49 6131 9084 ext 0 info@biontech.de
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04380701
Other Study ID Numbers  ICMJE BNT162-01
2020-001038-36 ( EudraCT Number )
U1111-1249-4220 ( Other Identifier: WHO UTN )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party BioNTech SE
Study Sponsor  ICMJE BioNTech SE
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: BioNTech Responsible Person BioNTech SE
PRS Account BioNTech SE
Verification Date April 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP